Is your company currently looking to establish or increase vaccine manufacturing capacity? The race to meet demand for COVD-19 vaccines (and therapies) has dramatically reshaped the planning and execution of pharmaceutical manufacturing capital projects. And when it comes to vaccines, a proper understanding of the specific synthesis and formulation processes involved – and the current challenges therein – is essential for success. Without it, capital projects cannot be executed on time or budget in this highly challenging and dynamic environment.
In this fourth installment of the multi-part webinar series, we review the synthesis and formulation processes for the various vaccine types and do a deep-dive on live (attenuated) and inactivated whole organism vaccines. We outline the implications for any company currently looking to establish or increase manufacturing capacity for these vaccine platforms.
Join our subject matter expert Christian Lavarreda on this fourth installment of "Vaccine Synthesis and Formulation Processes" on Thursday, September 23, 2021. This event will last approximately 45 minutes and include an interactive Q&A session.